Skip to content
Biodatica
Start free

SHASQI, INC.

SAN FRANCISCO, CA

OncologyADCGrant-only
Compare Sign in to watch

What changed

NIH R44 · $1.1M · CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry

9mo agoNew grantSep 24, 2025Source filing (opens the source filing in a new tab)

Momentum

40no change

Momentum 40 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R44 · $1.1M · non-dilutive

    Sep 25, 2025

    SHASQI, INC. · PI MEJIA ONETO, JOSE M · NCI · award ends Aug 31, 2027 · CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry

    NIH RePORTER · NIH RePORTER 11254074 (opens the source filing in a new tab)

  2. Grant

    R44 · $432k · non-dilutive

    Sep 6, 2024

    SHASQI, INC. · PI MEJIA ONETO, JOSE M · NCI · award ends Aug 31, 2026 · Antigen-targeted activation of Topo1 inhibitors via click chemistry

    NIH RePORTER · NIH RePORTER 11187221 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources